hVIVO Share News (HVO)

Positive results from FLU-v study welcomed by hVIVO

(Sharecast News) - Clinical development services company hVIVO announced positive results for the primary endpoint, following completion of analysis of samples by NIAID, and additional results from the Phase IIb viral challenge study of FLU-v.

WINNERS & LOSERS SUMMARY: Halfords Drops After Weak Third Quarter

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.5%. The supermarket chain revealed a a

hVIVO Meets Primary Endpoint In Phase II Vaccine Flu Study

LONDON (Alliance News) - hVIVO PLC on Thursday said it achieved the primary endpoint in a phase II study of FLU-v, a vaccine candidate for influenza.The company said that the study showed a

Mosquito saliva peptide vaccine has hVIVO upbeat

(Sharecast News) - Clinical development services business hVIVO confirmed on Wednesday that the National Institutes of Health had presented partial preliminary results from the recently-completed Phase I study of AGS-v at the American Society of Tropical Medicine and Hygiene's 67th annual conference in New Orleans.

hVIVO Gets Encouraging Results From Mosquito Disease Vaccine Proposal

LONDON (Alliance News) - hVIVO PLC said Wednesday preliminary results from the first in-man study of AGS-v, a proposed mosquito-borne disease vaccine, met primary objectives and endpoints safety a

hVIVO lauds sales pipeline and large contract as revenues jump

(Sharecast News) - Drug development services provider hVIVO achieved its "strongest potential sales pipeline" for several years, executive chairman Trevor Phillips said on Thursday.

hVIVO First Half Loss Narrows On Cost Savings, CFO Yeatman Resigns

LONDON (Alliance News) - hVIVO PLC said Thursday that increased revenue generation and ongoing costs savings led to a narrowed loss for the first half.The clinical development services also

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 14 September JD WetherspoonHalf Year ResultsTriple Point Social HousingHalf Year

hVIVO Achieves Primary And Secondary Endpoints In Flu Vaccine Study

LONDON (Alliance News) - Shares in hVIVO PLC rose on Monday after the scientific research company announced positive results from the study of its flu vaccine.Shares were trading up 25% at

hVIVO CEO Steps Down In Favour Of Executive Chair As Loss Narrows

LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor

hVIVO Receives Encouraging Initial Results From FLU-v Vaccine Study

LONDON (Alliance News) - hVIVO PLC said on Monday it received encouraging initial results from a Phase IIb study examining FLU-v as a potential universal vaccine against is by

UPDATE: hVIVO Says Two Clinical Studies Fail To Meet Primary Endpoints

DIRECTOR DEALINGS: hVIVO Chairman And Non-Executive Acquire Shares

hVIVO revises expectations after accounting anomaly

(ShareCast News) - Specialty biopharma company with clinical testing capabilities, hVIVO, announced a trading update regarding the accounting treatment of the company's joint venture investment in Imutex on Wednesday. The AIM-traded firm said that due to accounting rules, revenue from the Phase IIa

hVIVO launches groundbreaking asthma study

(ShareCast News) - Human disease models pioneer hVIVO announced on Friday that its landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus at hVIVO's London-based clinical research unit. The AIM-traded firm said the hVIVO asthma stratifica